Hasil Pencarian (1)
small molecule | CAS: 1446502-11-9
Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of…
Kategori:
AminesAntineoplastic AgentsAntineoplastic and Immunomodulating Agents
+62
Target Protein:
Isocitrate dehydrogenase [NADP] cytoplasmicIsocitrate dehydrogenase [NAD] subunit alpha, mitochondrialIsocitrate dehydrogenase [NAD] subunit beta, mitochondrial
+2
Waktu ParuhEnasidenib has a te…
Vol. DistribusiThe mean volume of …
KlirensEnasidenib has a me…
Genetik
-